Five things for pharma marketers to know: Thursday, March 4, 2021
Health insurers launch program to vaccinate 2 million seniors; Studies show Brazil variant reinfected former COVID patients; Ovid Therapeutics sells soticlestat to Takeda.
Health insurers launch program to vaccinate 2 million seniors; Studies show Brazil variant reinfected former COVID patients; Ovid Therapeutics sells soticlestat to Takeda.
This week’s Vaccine Project newsletter is 3,062 words long and will take you nine minutes to read.
White House brokers Merck/J&J deal on vaccine production; Texas relaxes COVID mandates; Trump Administration diverted hospital funds to Operation Warp Speed.
Johnson & Johnson vaccine to start being administered in next few days; Merck to acquire head and neck cancer therapy xevinapant; U.S. COVID-19 cases plateau at ‘very high number.’
Mass vaccinations in Israel result in a drop of severe COVID-19 cases; Amgen’s tezepelumab shows success in PHASE III Navigator study; Cigna’s Evernorth acquires MDLive.
U.S. administers 68 million vaccine doses; Sarepta’s Duchenne muscular dystrophy drug gains FDA approval; Merck acquires Pandion for $1.85 billion.
This week’s Haymarket Media Coronavirus Briefing is 1,977 words and will take you eight minutes to read.
Moderna sends vaccine targeting COVID variants to NIH; FDA scientists endorse Johnson & Johnson vaccine; Biden administration to send 25 million masks to low-income communities.
This edition of the Vaccine Project newsletter is 3,024 words long and will take you nine minutes to read.
Pfizer and Moderna to double vaccine production; Latin American leaders accuse Pfizer of ‘bullying’ them over vaccine negotiations; Becerra appears before Senate confirmation hearing.